Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers A > Headlines for Angiotech Pharmaceuticals, Inc. > News item |
Merrill has Angiotech at buy
Angiotech Pharmaceuticals Inc. was rated at a buy by Merrill Lynch analyst Hari Sambasivam. The analyst updated his model following the company's second-quarter earnings call. While the changes in revenues and earnings are not that different from Merrill's prior estimates, Taxus sales estimates were revised to be more in line with estimates for Boston Scientific. Shares of the Vancouver, B.C.-based medical technology company were down 38 cents, or 3.21%, at $11.47, on volume of 372,346 shares versus the three-month running average of 384,089 shares. (Nasdaq: ANPI)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.